Bluejay Diagnostics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bluejay Diagnostics, Inc. (NASDAQ: BJDX) on March 23, 2022. The filing reports a significant change in executive leadership, specifically the appointment of a new Chief Financial Officer and the resignation of the incumbent.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
- Appointment of CFO: Kenneth Fisher was appointed Chief Financial Officer effective March 23, 2022.
- Resignation of CFO: Gordon Kinder resigned from his position as Chief Financial Officer effective immediately on March 23, 2022.
- Compensation Structure: Mr. Fisher's initial annual salary is set at $275,000, increasing to $300,000 on January 1, 2023. He is eligible for a targeted annual bonus of 40% of his base salary, payable in cash and/or stock options.
- Equity Grant: Mr. Fisher received a ten-year option to purchase 65,000 shares of common stock at an exercise price of $1.31 per share. Vesting terms include 5,000 shares fully vested at grant and 60,000 shares vesting in three equal annual installments.
- Severance: In the event of termination without "cause," Mr. Fisher is entitled to six months of base salary and a pro rata portion of the target annual bonus.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or discussion of risks and contingencies. Management commentary is limited to the background of the new CFO, noting his experience as a Certified Public Accountant and former CFO of Meridian Bancorp, Inc.
Key Facts for Investor Verification
- Verify the effective date of the CFO transition (March 23, 2022) and the immediate resignation of the prior CFO.
- Confirm the total equity grant size (65,000 shares) and the exercise price ($1.31) relative to the current market price.
- Review the vesting schedule to understand the retention timeline for the new CFO (three-year cliff for the majority of the grant).
- Check subsequent filings for any changes to the compensation committee's determination of the annual bonus.